Founded in partnership with Mayo Clinic, Sendero Biotechnology is a Michigan-based biotechnology company focused on developing novel oncology therapies. The company's core mission is to advance cancer treatment by targeting the TRAIL pathway, specifically through therapies against the immune evasion target TRAILshort. By leveraging cutting-edge research and technology licensed from Dr. Andrew Badley's lab, Sendero aims to bring innovative solutions to the oncology market.
Notable affiliations include the prestigious Mayo Clinic and Dr. Andrew Badley, whose research underpins the company's technological advancements. Although operating in stealth mode, Sendero Biotechnology has made significant strides in the field of cancer therapy. Its impact lies in its potential to revolutionize cancer treatment by addressing immune evasion mechanisms, thereby improving patient outcomes and advancing the broader field of oncology.
